B. Riley raised the firm’s price target on TG Therapeutics (TGTX) to $55 from $53 and keeps a Buy rating on the shares. The firm believes the company is positioned for multi-year Briumvi U.S. sales growth. It sees the drug being on track to exceed $1B in the next few years. Riley recommends using the post-earnings selloff in shares of TG as a buying opportunity.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics says enrollment commenced for Phase 3 trial of BRIUMVI
- Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz
- TG Therapeutics completes share repurchase program, authorize new $100M program
- Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges
- TG Therapeutics files automatic mixed securities shelf